The mean number of IL-2 doses in the first 2 cycles in patients who had a best overall response of CR or PR versus SD or PD was similar (melanoma responder vs non-responder mean = 21.1 SD = 3.7 vs mean = 19.5 SD = 4.3 and RCC mean = 18.5, SD = 3.7 vs mean = 17.7 SD = 4.7). The gene discussed is IL2; the disease is melanoma.